Post-ASCO Scoreboard Part 2
Following up on the previous post we can review selected small and mid-stocks participating in the ASCO Conference look at performance over 3 months from March 14 to June 13 including a 7% correction in the market overall. Most biotech stocks peaked in Q2 2011. See previous post for ASCO news...
ASCO Winners Part 1: ARIA,ECYT,INCY
Despite an ASCO "sell on the news" and a severe Q2 correction some mid and small cap cancer related stocks are still up although off their highs. See commentary and news from earlier posts. More on these and others...
Nasty Day, Nasty Month, Nasty News: Cliches Rule
All major indices and sectors sold off today making it 7 bad days out of 8 and a 6.37% correction in the S&P 500 over 30 days. The NASDAQ is now down 7.94% since May 11. Remember "sell in May and go away" ? Things were not much better in biotech-land with the IBB down 5% over one month....
Biotech Stocks Go Green Except Vertex (VRTX)
The market rallied on the seventh day after six days of losses but we still have a few hours to go. The Dow is up 0.96% and the NAZ is up 0.64%.Life Science stocks are strong overall with mid-caps up 0.75%. Diagnostics and tools are the strongest sector and within the Raygent Portfolio all...
June Gloom Continues : ASCO Buzz is Off But VRUS Soars
Stocks Down for Sixth Straight Session: Biotechs still up Over 10% YTD As we wind down from ASCO news with few catalysts ahead, investors and traders will regroup and rebalance their portfolios. The NASDAQ index is down 21 pts off 0.77% and component biotech stocks in the NASDAQ-100 are...